Acquisitions - Narrative (Details)	0 Months Ended	1 Months Ended	5 Months Ended	12 Months Ended					0 Months Ended		0 Months Ended			0 Months Ended									0 Months Ended			1 Months Ended										0 Months Ended								0 Months Ended		0 Months Ended	12 Months Ended			0 Months Ended	12 Months Ended	0 Months Ended				12 Months Ended	0 Months Ended					1 Months Ended	12 Months Ended			0 Months Ended					12 Months Ended		0 Months Ended					1 Months Ended		12 Months Ended	0 Months Ended
	Jul. 15, 2014 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Nov. 25, 2014 EUR (€)	Aug. 08, 2014 USD ($)	Aug. 07, 2012 Blockade Medical LLC USD ($)	Aug. 07, 2012 Blockade Medical LLC	Oct. 04, 2013 Wells Fargo Credit Agreement USD ($)	Dec. 19, 2012 Wells Fargo Credit Agreement USD ($)	Aug. 07, 2012 Special Membership Units Blockade Medical LLC	Nov. 25, 2014 License agreements and trademarks	Aug. 08, 2014 License agreements and trademarks	Jul. 15, 2014 License agreements and trademarks	Dec. 20, 2013 License agreements and trademarks	Dec. 20, 2013 License agreements and trademarks USD ($)	Sep. 10, 2013 License agreements and trademarks USD ($)	Dec. 31, 2014 License agreements and trademarks USD ($)	Dec. 31, 2013 License agreements and trademarks USD ($)	Sep. 10, 2013 License agreements and trademarks USD ($)	Aug. 08, 2014 Distribution agreements	Aug. 21, 2012 Distribution agreements USD ($)	Jan. 05, 2012 Distribution agreements	May 31, 2012 Distribution agreements USD ($)	Jan. 31, 2012 Distribution agreements USD ($)	Dec. 31, 2014 Distribution agreements USD ($)	Aug. 08, 2014 Distribution agreements USD ($)	Dec. 31, 2013 Distribution agreements USD ($)	Aug. 21, 2012 Distribution agreements USD ($)	Jan. 05, 2012 Distribution agreements USD ($)	Dec. 31, 2014 Developed technology USD ($)	Aug. 08, 2014 Developed technology USD ($)	Dec. 31, 2013 Developed technology USD ($)	Jan. 05, 2012 Customer Lists	Dec. 31, 2014 Customer Lists USD ($)	Dec. 31, 2013 Customer Lists USD ($)	Jan. 05, 2012 Customer Lists USD ($)	Dec. 31, 2014 Trademarks USD ($)	Dec. 31, 2013 Trademarks USD ($)	Dec. 31, 2014 Non-compete agreements USD ($)	Dec. 31, 2013 Non-compete agreements USD ($)	Aug. 27, 2012 License Agreement Terms USD ($)	Aug. 27, 2012 License Agreement Terms USD ($)	May 08, 2014 GMedix USD ($)	Dec. 31, 2014 GMedix USD ($)	Dec. 31, 2013 GMedix USD ($)	May 08, 2014 GMedix	Oct. 04, 2013 Datascope USD ($)	Dec. 31, 2013 Datascope USD ($)	Oct. 04, 2013 Datascope Developed technology	Oct. 04, 2013 Datascope Customer Lists	Oct. 04, 2013 Datascope Trademarks	Oct. 04, 2013 Radial Assist USD ($)	Dec. 31, 2013 Radial Assist USD ($)	Oct. 04, 2013 Radial Assist Developed technology	Oct. 04, 2013 Radial Assist Customer Lists	Oct. 04, 2013 Radial Assist Trademarks	Dec. 31, 2012 Thomas Medical Products, Inc USD ($)	Dec. 19, 2012 Thomas Medical Products, Inc	Dec. 31, 2012 Thomas Medical Products, Inc USD ($)	Dec. 31, 2013 Thomas Medical Products, Inc USD ($)	Dec. 31, 2012 Thomas Medical Products, Inc USD ($)	Dec. 19, 2012 Thomas Medical Products, Inc USD ($)	Dec. 19, 2012 Thomas Medical Products, Inc Developed technology	Dec. 19, 2012 Thomas Medical Products, Inc Customer Lists	Dec. 19, 2012 Thomas Medical Products, Inc Trademarks	Dec. 19, 2012 Thomas Medical Products, Inc Non-compete agreements	Nov. 19, 2012 MediGroup USD ($)	Dec. 31, 2012 MediGroup USD ($)	Nov. 19, 2012 MediGroup USD ($)	Nov. 19, 2012 MediGroup Developed technology	Nov. 19, 2012 MediGroup Customer Lists	Nov. 19, 2012 MediGroup Trademarks	Nov. 19, 2012 MediGroup Non-compete agreements	Jan. 31, 2012 Ostial Solutions, LLC USD ($)	Aug. 31, 2012 Ostial Solutions, LLC USD ($)	Jan. 31, 2012 Ostial Solutions, LLC USD ($)	Dec. 31, 2012 Ostial Solutions, LLC USD ($)	Jan. 31, 2012 Ostial Solutions, LLC Developed technology	Jan. 31, 2012 Ostial Solutions, LLC Customer Lists	Jan. 31, 2012 Ostial Solutions, LLC Trademarks	Jan. 31, 2012 Ostial Solutions, LLC Non-compete agreements
Business Acquisition [Line Items]
Payments to acquire intangible assets		$ 625,000	$ 3,000,000	$ 1,714,000	$ 1,617,000	$ 1,460,000												$ 700,000	$ 250,000					$ 250,000		$ 1,000,000	$ 1,500,000																	$ 750,000
Liabilities incurred in agreement		1,000,000	1,000,000	1,000,000
Contingent consideration, liability							1,500,000	3,000,000																																																																403,000							4,300,000
Useful life														10 years	12 years	10 years	4 years		10 years				3 years	10 years	12 years																			3 years								10 years	6 years	15 years			10 years	6 years	15 years							8 years	12 years	15 years	3 years				8 years	8 years	15 years	7 years					15 years	8 years	15 years	5 years
Intangible assets																													200,000					3,800,000
Payments to acquire investments	752,000								1,000,000																																					1,800,000
Cost method investments, shares acquired													422,594																																				737,628
Cost method investments, ownership percentage										11.90%																																							19.00%
Payments to acquire businesses, net of cash acquired				5,927,000	31,600,000	192,762,000																																									1,450,000	350,000
Accrued liabilities		33,826,000	33,826,000	33,826,000	27,702,000													350,000				250,000
Finite-lived intangible assets, gross																		700,000		8,995,000	3,783,000	250,000						5,376,000		5,176,000							20,452,000	20,626,000		7,298,000	7,622,000	1,029,000	1,029,000
Payments to acquire businesses																																																		27,500,000					2,500,000							167,000,000								4,000,000								6,500,000	10,000,000
Income before tax																																																			1,600,000					191,000								51,000
Weighted average useful life																																				5 years														10 years					10 years 0 months 27 days						8 years 6 months 18 days									8 years 1 month 24 days							14 years 7 months 6 days
Long-term debt issuance costs				0	798,000	3,706,000					798,000	3,700,000
Due date in relation to first commercial sale																			30 days
Liabilities incurred																																																												445,000
Net sales																																																															1,900,000								169,000									457,000
Goodwill, period increase (decrease)																																																															381,000
Acquired receivables																																																																	6,500,000
Estimated uncollectible trade receivables acquired																																																																	34,000
Acquisition-related costs																																																																2,700,000
Contingent consideration, payment, 2013																																																																						150,000
Contingent consideration, payment, 2014																																																																						150,000
Contingent consideration, payment, 2015																																																																						150,000
Contingent consideration, potential payment, 2016																																																																						150,000
Contingent consideration, potential payment, 2017																																																																						150,000
Contingent consideration, potential payment, 2018																																																																						150,000
Contingent consideration, potential payment, 2019																																																																						150,000
Contingent consideration, potential payment, 2020																																																																						150,000
Contingent consideration, potential payment, 2021																																																																						150,000
Contingent consideration, potential payment, 2022																																																																						150,000
Potential payment, annual increase in net sales, minimum percent																																																																						8.00%
Intangible assets purchased																				7,172,000	2,534,000							3,091,000		3,396,000	250,000	2,500,000	79,172,000		91,052,000		7,258,000	9,669,000	95,000	5,219,000	5,778,000	393,000	630,000		750,000
Contingent consideration, potential payment																								250,000																																																					13,500,000
Acquired in-process research and development				$ 0	$ 0	$ 2,450,000